# Lepu Medical Technology (Beijing) Co.

Lepu Medical Technology (Beijing) Co. is a Medical Equipment Manufacturing based in Beijing, China.

## Overview

- **Organization type:** Medical Equipment Manufacturing
- **Headquarters:** Beijing, China
- **Region:** North America
- **Address:** Beijing, China
- **Founded:** 1999
- **Assets under management:** Undisclosed
- **Website:** lepumedical.com
- **LinkedIn:** https://www.linkedin.com/company/lepu-medical

## Regulatory record

- **Reports private funds:** No

## About

Lepu Medical Technology was founded in 1999 by Hua Pu in Beijing, China. The company went public on the Shenzhen Stock Exchange in 2009 (ticker: 300003) and remains controlled by the founding family. Hua Pu serves as chairman; his son Hua Li serves as vice president. The underlying wealth originates from medical device manufacturing and distribution. The firm holds a diversified portfolio spanning cardiovascular interventional devices (stents, catheters, pacemakers), industrial technology through subsidiaries like Beijing Lepu Precision Medical Technology, and real estate investments. Geographically, Lepu operates across China, the United States (offices in Pasadena and New York), Europe (Paris, Hellerup), and distributes products to over 100 countries. The company has made acquisitions including the 2011 purchase of Beijing Huaqing Medical Equipment and the 2016 acquisition of Cardiologs, a French digital health company, for an undisclosed sum. The firm maintains co-investment relationships with Chinese state-backed funds and international partners. Lepu employs approximately 8,000 people globally. The company operates a medical device manufacturing plant in Beijing, a research center in Pasadena, and a European distribution hub in Hellerup. The firm maintains philanthropic foundations focused on cardiovascular health in rural China. The most recent operational event of note is the 2023 launch of its next-generation drug-eluting stent in China (per public filings). Lepu's structural differentiator is its hybrid identity as a publicly traded company where the founding family retains majority control, allowing it to operate with the capital access of a listed firm while maintaining the long-term orientation and discretion of a family-controlled enterprise. Its global office network—unusual for a Chinese medical device maker—supports both operational expansion and diversified capital deployment across geographies.

## Sectors

- Healthcare Services
- MedTech
- Industrial Tech
- Real Estate

## Offices

- Pasadena, California, United States
- New York, New York, United States
- Shanghai, China
- Paris, France
- Hellerup, Denmark

## People

- Hua Pu — Founder
- Hua Li — Vice President

## Questions

### Who controls investment decisions at Lepu Medical Technology?

Lepu is controlled by the founding Hua family, with Hua Pu serving as chairman. Hua Li, his son, serves as vice president. The company's board of directors approves major capital allocation, including acquisitions and real estate investments. The founding family maintains majority voting control through their shareholding structure (per public filings).

### What is Lepu's known posture on co-investments and partnerships?

Lepu has engaged in co-investments with Chinese state-backed funds and international partners for acquisitions. The 2016 acquisition of Cardiologs involved co-investment from European venture partners. The firm also collaborates with academic hospitals and research institutions in China, the U.S., and Europe for clinical trials and device development (per public filings and press releases).

### What investment stages and sectors does Lepu typically target?

Lepu targets growth-stage and strategic acquisitions primarily in medical technology, including cardiovascular devices, digital health (Cardiologs), and precision medical equipment. The firm also makes real estate investments and holds industrial technology subsidiaries. The company does not actively target early-stage venture investments or pure financial assets; its investments are predominantly strategic and operational.

### Is Lepu's capital deployment purely internal or does it make fund commitments?

Lepu's capital deployment is primarily direct—through acquisitions, R&D investment, and real estate holdings. The firm does not publicly report allocations to external fund managers. Co-investments with state-backed funds and international partners occur on a deal-by-deal basis.

## Related profiles

- [Galway Insurance Holdings](https://altss.com/profile/galway-insurance-holdings)
- [Glia Technologies](https://altss.com/profile/glia-technologies)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/lepu-medical-technology-beijing-co

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology